Results 121 to 130 of about 3,015 (158)

Simeprevir

Reactions Weekly, 2017
  +4 more sources

Simeprevir

Reactions Weekly, 2016
  +4 more sources

Simeprevir/sofosbuvir

Reactions Weekly, 2017
  +5 more sources

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Simeprevir

2018
openaire   +1 more source

Simeprevir

Reactions Weekly, 2014
openaire   +1 more source

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Lancet, The, 2014
Gregory J Dore, Graham R Foster, Michael W Fried   +2 more
exaly  

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Hepatology, 2013
Michael W Fried, Maria Buti, Gregory J Dore   +2 more
exaly  

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Hepatology, 2016
Eric Lawitz
exaly